Plasma cytokine levels and HIV-specific immune responses during acute/early HIV infection

Abstract

It is believed that initial encounter between HIV and the human host triggers a complex series of events that dictate future disease course. Inter-individual differences among the host-players involved in these processes seem to early determine different rates of disease progression. Here we were aimed at studying the relationship between innate and adaptive soluble immune mediators, HIV-specific T-cell response and the course of acute infection. Methods Plasma levels of 37 cytokines were measured by Luminex technology in different groups of volunteers: 10 healthy donors (HD) and 50 HIV infected-subjects: 10 chronics, 12 aviremic controllers (EC) and 28 subjects enrolled during acute infection (AI). All HIV patients were offHAART. Frozen PBMCs from the same individuals were used to determine HIV-specific T-cell responses by IFNgamma ELISPOT. Data was compared inter- and intragroups and correlated to viral load (VL), CD4 T cell counts and both virological (VL) and immunological (CD4 count) set-points (in AI), using parametric and non-parametric statistics. Results Compared to HD, cytokines significantly elevated during acute and chronic infection included IL-1alfa, IL-10, IP-10 and TNF-alfa. Conversely, IL-12p40 and the macrophagederived chemokine (MDC) were only significantly elevated in chronics and not in AI subjects who showed similar levels to HD and even EC. Moreover, levels of IL-12p40, IL-12p70 and MDC directly correlated with CD4 T-cell count among chronics and both CD4 T-cell count and immunological set point in AI. Regarding HIV-specific T-cell response during AI, proportion of Gag-specific and Nef-specific cells significantly correlated (directly and inversely, respectively) with immunological set point. Conclusion Both early and late components of the immune system help preserve CD4 T-cell subset in HIV+ subjects: key cytokines involved in the initiation and regulation of cellular immune response and anti-Gag specificity of effector T-cells. These features should be taken into account during vaccine formulation design to boost favorable results.